Topics

Explore topics

#immunodeficiency

Follow to get notified about new posts with this tag
genexi
health
7y
FDA Approves Xembify for Primary Immunodeficiencies
FDA Approves Xembify for Primary Immunodeficiencies
The US Food and Drug Administration (FDA) has approved Grifols’ first immunoglobulin Xembify®, 20% solution for the treatment of primary immunodeficiencies in patients as young as 2 years old.
1
maheshgore
human
8y
!Low reputation account with an unverified outbound link, Reveal content
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Business Overview and Top Key Players - Gilead Sciences, AbbVie, Bristol-Myers Squibb Company
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Business Overview and Top Key Players - Gilead Sciences, AbbVie, Bristol-Myers Squibb Company
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market size is projected to experience significant growth from 2017 to 2024. Human immunodeficiency virus therapeutics market size should witness tremendous
0
1
market-report
primary
8y
Primary Immunodeficiency Diseases Treatment Market | 2017-2024 Industry Research Report
Primary Immunodeficiency Diseases Treatment Market | 2017-2024 Industry Research Report
Primary Immunodeficiency Diseases Treatment Market evaluates the growth of the industry and estimates future prospects based on comprehensive research. Also provides the market size, share, growth, trends
rasavel2
adult-onset
8y
Adult-onset immunodeficiency syndrome
Adult-onset immunodeficiency syndrome
Adult-onset immunodeficiency syndrome is a provisional name for a newly diagnosed immunodeficiency illness. The name is proposed in the first public study to identify the syndrome.[1] It appears to be
bhardwaj
virus
9y
HIV: 35 years later
HIV: 35 years later
After 35 years of identifying HIV as a cause of AIDS, there is still stigmatization and ignorance. On January 23, 1983, Luc Montagnier, of the Pasteur Institute in Paris, identified for the first time

Discover communities

Explore communities
Create your community